article thumbnail

Vicore initiates clinical proof-of-concept study of endothelial dysfunction 

Drug Discovery World

Official comments “Measuring endothelial dysfunction with the EndoPAT technology in drug trials is a cost-effective and robust method for early documentation of proof-of-concept in pulmonary, renal and vascular diseases” says Elin Rosendahl, VP Clinical Operations, Vicore Pharma.

article thumbnail

Cardiovascular Clinical Trials with Patient Diversity: Challenges and Considerations

XTalks

This started back in 1993 when the FDA established guidelines to increase diversity by gender and race/ethnicity of participants in clinical trials that were contributing to new drug approvals. An analysis of trials that supported FDA approvals of new cardiometabolic drugs from 2008 to 2017.